Lineage Cell Therapeutics, Inc. LCTX
0.82 USD +0.02 (+2.60%)
Regular-session close
0.80 -0.02 -1.94%
After hours · Nov 17, 7:29 PM ET
0.7699 Day range 0.8754
0.7699 52-week range 1.99
- YTD
- -51.15%
- 1 year
- -53.11%
News
marketbeat.com What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call Lineage Cell Therapeutics NYSEAMERICAN: LCTX has acquired privately held NeuroAirmid Therapeutics, adding an experimental Huntington's disease cell therapy to its clinical pipeline as the company…
seekingalpha.com Lineage Cell Therapeutics, Inc. (LCTX) Q3 2026 Earnings Call Transcript Lineage Cell Therapeutics, Inc. (LCTX) Q3 2026 Earnings Call Transcript
zacks.com Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.13 per share a year ago.benzinga.com Lineage Acquires NeuroAirmid Therapeutics Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s DiseaseAcquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease…
businesswire.com Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q3 2026 Earnings Release.
businesswire.com Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington's Disease CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic,…
businesswire.com Lineage Provides Update on ReSonance® Program for Hearing Loss CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel,…
defenseworld.net Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Climb 8.7% – Here’s What Happened Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) shares were up 8.7% during trading on Friday. The company traded as high as $1.04 and last traded at $1.03. Approximately…
businesswire.com Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--AlloSCOPE 5D Patent Release.
marketbeat.com Lineage Cell Therapeutics Q2 Earnings Call Highlights Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease,…
seekingalpha.com Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
zacks.com Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.
businesswire.com Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
marketbeat.com Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being…
seekingalpha.com Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
businesswire.com Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel,…
businesswire.com Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
marketbeat.com Lineage Cell Therapeutics Q1 Earnings Call Highlights Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program…
seekingalpha.com Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
zacks.com Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
businesswire.com Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
